12:00 AM
Sep 16, 2013
 |  BC Week In Review  |  Company News  |  Deals

Inovio, Roche deal

Inovio granted Roche exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800, as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche also has an option to license additional cancer...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >